


What's New in


CURE ID v4.2

Case Report Forms Update
Improved Filter and Search Feature
New Activity User Interface
Push Notification Center
Bug Fixes

More Updates to come related to extraction of EHR data to CURE ID and Oncology/Rare Disease versions of the app and forms




Visit the CURE ID website for more information.
<https://cure.ncats.io>



CDRC Impact Story

IMPACT STORY



Drug Repurposing Provides Big Impact for Patients

C-Path's CDRC is positioned to inform future clinical trials for diseases of high unmet medical need with real-world clinical outcome data

Rare Disease Day

Millions of patients struggle every day with diseases that lack adequate treatment options. For many rare and orphan diseases, approved therapies are either absent or unsatisfactory, and healthcare providers may need to use existing drugs in novel ways for patients with difficult-to-treat conditions. Check out our Impact Story for #RareDiseaseDay featuring Shira Strongin & David Fajgenbaum, two very important people contributing to the CDRC and CURE ID project.

[Read more](#)

Publication Announcement

Leveraging the SCCM Discovery VIRUS COVID-19 Registry to Evaluate Drug Repurposing Research Datasets

Authors: Smith Heavner, Kerry H., Michael Pauley, Pamela Dasher, Laksika Banu Sivaraaj, Jagdeep Podichetty, Vishakha Kumar, Marco Schito, Rahul Kashyap.

This is a collaboration between Critical Path Institute (C-Path), Prisma Health, Mayo Clinic and Society of Critical Care Medicine.

[Read more](#)

Meet our Annual Meeting Speakers



Smith Heavner

Senior Scientific Director

CURE Drug Repurposing Collaboratory (CDRC)

Dr. Smith Heavner, PhD, RN, (he/they) serves as Senior Scientific Director of the CURE Drug Repurposing Collaboratory, a private-public partnership of the Critical Path Institute, the Food and Drug Administration, and the National Institutes of Health National Center for Advancing Translational Science. He earned his PhD in Applied Health Research and Evaluation from Clemson University in 2021 and completed a one year post-graduate training in clinical trial design and analysis at Harvard Medical School in 2023. As a nurse, Dr. Heavner specializes in critical care and emergency medicine with more than ten years of clinical experience and is an active member of the Society for Critical Care Medicine including serving on the core committee of the Discovery Network VIRUS COVID-19 Registry and the Data Outcomes and Definitions Workgroup. Dr. Heavner is a mixed-methods evaluation scientist with expertise in dissemination and implementation science, informatics, real world data, and regulatory science. They hold two adjunct faculty appointments in the Department of Public Health Sciences at Clemson University and the Department of Biomedical Sciences at the University of South Carolina School of Medicine Greenville. Dr. Heavner will be presenting at the CDRC Annual Meeting about automating data extraction from EHRs.



Rosie Lovett

Head of repurposing medicines program

Medicines Repurposing Program England

Dr. Rosie Lovett, PhD is a scientist with expertise in research and health technology assessment. She leads NHS England's repurposing program, which aims to get existing medicines used for new conditions (not just the condition the medicine was originally intended to treat). She is an Honorary Senior Research Fellow at SchARR, University of Sheffield. She previously worked in the science policy and research program and technology appraisals program at NICE and as a researcher at UCL. Rosie will be speaking at the CDRC Annual Meeting about the Medicines Repurposing program of England.



Vidula Sukhatme

Morningside Center Co-founder

Mrs. Sukhatme, CEO of GlobalCures, Inc., is a co-founder of the Morningside Center for Innovative and Affordable Medicine. She has 20 years of experience in information systems in health care environments. She holds two master of science degrees: one in mathematics from Northeastern University and a second in epidemiology from Harvard T.H. Chan School of Public Health.

Save the date




CURE Drug Repurposing Collaboratory Annual Meeting

April 18th- 20th, 2023, Hyatt Regency Crystal City

2799 Richmond Highway - Arlington, Virginia 22202

[Check out the agenda now](#)



Events

In the past:

Critical Path to Women Leading in Science

Feb. 6, 2023 | 1:30 PM Eastern Time (US and Canada)

C-Path had a 90-minute roundtable discussing the Critical Path Institute's programs and consortia, highlighted by various women leaders at this public-private partnership. The team discussed how C-Path contributed to transforming and accelerating the medical product development process, as well as their personal professional development journey. The roundtable included an interactive Q&A session, where the audience could ask specific questions about C-Path activities and, more generally, scientific career paths. Registration was free and open to the public.

Rare Disease Day at FDA

#FDA Rare Disease Day: "Intersections with Rare Diseases – A patient focused event"

Feb. 27, 2023 | 9:00 AM – 4:45 PM Eastern Time (US and Canada)

FDA hosted Rare Disease Day, a virtual public meeting, on February 27, 2023, in global observance of Rare Disease Week. This year's theme was "Intersections with Rare Diseases – A patient focused event." Participants had the unique opportunity to hear directly from the FDA on initiatives to advance medical product development for rare diseases. They also engaged with the FDA to provide their perspectives as patients, caregivers or family members. Participants learned about the considerations and challenges associated with clinical trials in small populations. They also heard from medical students on rare disease education for medical professionals.

Rare Disease Day at NIH

Feb. 28, 2023 | 10:00 AM – 5:00 PM Eastern Time (US and Canada)

Rare Disease Day at NIH was held in person at NIH Main Campus (Natcher Conference Center) on Tuesday, Feb. 28, 2023, from 9 a.m. to 5 p.m. EST. There was also a virtual livestream via NIH VideoCast with the event archived for replay afterward. The event agenda featured panel discussions, rare diseases stories, exhibitors and scientific posters.

Coming up:

SickKids Pediatric Infectious Disease Update

March 4, 2023 8:45 AM – 1:00 PM Eastern Time (US and Canada)

The SickKids ID division is hosting an all VIRTUAL conference on Peds ID. New and emerging infectious diseases have dominated pediatric practice in the past 3 years. This conference will highlight current and leading-edge pediatric infectious diseases knowledge and practices relevant to health care professionals working in pediatrics, infectious diseases, and family practice. #PedsID #IDTwitter Vaccines, COVID, UTI Updates and Keynote speaker Dr David Kimberlin.

[Register Here](#)

Critical Path for Rare Neurodegenerative Diseases: An Introduction to the Patient Community

March 15, 2023 | 9:30 AM Eastern Time (US and Canada)

You're invited to join C-Path to learn more about its Critical Path to Rare Neurodegenerative Diseases public-private partnership during this introductory webinar.

Attendees of the webinar will leave with an understanding of: The CP-RND strategic plan, its stakeholder groups and program deliverables, The envisioned impact of CP-RND on medical product development in rare neurodegenerative diseases, Perspectives from patients, regulators and the industry on the public-private partnership and the rare neurodegenerative disease community. The event will also include time for feedback and questions from participants.

[Register Here](#)


FDA to host virtual public meeting 'Patient-Focused Drug Development for Long COVID'

April 25, 2023

On April 25, the FDA is hosting a virtual public meeting called "Patient-Focused Drug Development for Long COVID." The meeting will provide the FDA the opportunity to obtain initial patient and patient representative input on the aspects of long COVID-19, including how it affects their daily life, symptoms that matter most to patients, their current approaches to treating long COVID-19, and what they consider when determining whether or not to participate in a clinical trial. This virtual public meeting will be conducted with live translation in both English and Spanish.

[View more](#)

CDRC Retreat in Tucson, AZ



The CURE Drug Repurposing Collaboratory, Critical Path Team met in Tucson, to work on upcoming projects, annual meeting topics, addressed team issues, and gained insight in what team members are doing in the Collaboratory.

During our time, we were able to meet out-of-state members and participated in team bonding.



Trending Articles

COVID Dramatically Increases Death Risk During Pregnancy: Study

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Physical interventions to interrupt or reduce the spread of respiratory viruses

Awareness Month



CURE ID/CDRC Social Media Ambassador


Looking to become a social media ambassador?

CURE ID is looking to recruit individuals interested in help promoting our web-based app. The platform enables healthcare providers to share their real-world experiences treating patients with repurposed drugs. We currently have 20 social media ambassadors and looking to expand.

This is an unpaid position but can win CURE ID/CDRC swag.

This is a competitive opportunity to bring on more followers, tweets, discussion posts, and win some swag!

If interested please reach out to cbassetti@c-path.org



Be Heard

Tell Your Drug Repurposing Story in 2023

Our Impact stories share the value and impact C-Path's and CDRC's work brings to patients, patient organizations, drug developers, the academic community, regulators and more. Enjoy and share! [Impact Stories](#) | [Critical Path Institute \(c-path.org\)](#)

Reach out to the Communication and Patient Engagement Manager, Claire Bassetti at cbassetti@cpath.org if interested in sharing your story through an Impact Story.






Joining the CDRC




The CURE Drug Repurposing Collaboratory (CDRC) is a public-private partnership initiated in June 2020 by C-Path and the U.S. Food and Drug Administration (FDA) in partnership with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).

If interested, please feel free to get involved with the CURE Drug Repurposing Collaboratory (CDRC), here: <https://c-path.org/cdrc>

Collaborators



Brought to you by



You received this email because you registered for CURE ID or signed up to receive our monthly newsletter. If you have any questions regarding this communication, please contact us at curesupport@nih.gov

